J&J Device Sales Growth Led By Diabetes, Vision Care As Q4 Stent Sales Sink
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's diabetes and vision care businesses generated the highest growth levels across the firm's device sector in the fourth quarter with each achieving operational growth of 12% compared to a year ago, the firm reported Jan. 23
You may also be interested in...
New Data Is Likely To Add Fuel To The Drug-Eluting-Stent Debate
New trial data presented at the American College of Cardiology annual meeting could be another obstacle to drug-eluting-stent manufacturers' efforts to reverse a year-long sales slump
New Data Is Likely To Add Fuel To The Drug-Eluting-Stent Debate
New trial data presented at the American College of Cardiology annual meeting could be another obstacle to drug-eluting-stent manufacturers' efforts to reverse a year-long sales slump
Hospital Survey Illustrates Drug-Eluting Stent Use Decline In Fourth Quarter
U.S. drug-eluting stent utilization rates markedly declined in the fourth quarter of 2006, most significantly in the last month of the year, as doctors chose to use bare-metal stents more frequently due to potential safety risks, a recent survey of about 65 hospitals suggests